Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans - Wikidata - awgldk - TriplyDB

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

http://www.wikidata.org/entity/Q35212433

about

Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis.Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases Rheumatoid Arthritis in Agricultural Health Study Spouses: Associations with Pesticides and Other Farm Exposures Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?High disease activity may not be sufficient to escalate care Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug.The incidence of upper and lower extremity surgery for rheumatoid arthritis among Medicare beneficiaries Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting.Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status.Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement.Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use Decision tool to improve the quality of care in rheumatoid arthritis Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Use of Decision Support for Improved Knowledge, Values Clarification, and Informed Choice in Patients With Rheumatoid Arthritis.Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment.Higher education is associated with a better rheumatoid arthritis outcome concerning for pain and function but not disease activity: results from the EIRA cohort and Swedish rheumatology register.A Multistakeholder Approach to Improving Quality in Rheumatoid Arthritis: Proceedings from the Rheumatoid Arthritis Quality Expert Medical Panel.Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009 Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients DMARD non-use in low-income, elderly rheumatoid arthritis patients: results of 86 structured interviews A new paradigm of quality of care in rheumatoid arthritis: how our new therapeutics have changed the game.Racial and ethnic disparities in rheumatoid arthritis.A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada.

P2860

Q27335103-81422674-B505-4402-AC45-0D5D5098F4AD Q28067382-E3440A68-9E80-4226-B40C-338C2135BD0D Q28393045-B75BB96F-BFC6-4827-B76F-7C2B535A828D Q30829469-9206B1A9-27C6-42DC-91C2-EC3D59318BB2 Q33577429-7DD11498-5717-46BE-A4F5-AA0F1E32F49F Q33812321-D92B953F-A10A-4696-9C9F-E7A7F7A59D67 Q33945242-06C0D1A5-52E3-4434-973E-647173DF54E2 Q33955222-C6E0F459-816B-4F03-ACA7-C46DF825462B Q34013509-8684DF34-13D3-4992-96D2-93DAADEAE60A Q34081364-392CE857-1926-4ECC-AD67-46CB84D3E506 Q34379235-9BB64EBC-2AD6-4FC2-8FEC-92480E92E6ED Q34851473-F48493FD-4850-4AAF-98C6-6854C96C8CDD Q34929669-C669D1D1-6AAF-42CE-B7E5-C0EF0CF8805E Q35131441-537179DC-B2B6-43F3-9DF7-4B69F17F3F90 Q35585144-E795862F-F1A4-4C73-8192-401F82A72B9A Q35695760-2C02F290-69A2-4C47-9510-2CA04FB40FBB Q35699981-F775ADE8-51AC-47A1-9595-A200312874F0 Q35731438-2BD9B2E7-611D-4DE9-BD38-163D4D8D3C58 Q35763883-AEDD8CBD-B90B-4E09-BD14-969D0580C603 Q35891191-271D3118-3666-482F-B8E1-C6A276CE68D8 Q35907737-108C227F-733D-4F06-8C52-1590BDE43C6D Q35996755-E338700F-0EEE-49C6-8A61-FB79AE6E7A58 Q36032715-416ADA92-7990-4886-B0AE-CD6C774DADBB Q36150089-94A93ED2-B52B-469B-B346-D16CB68614B3 Q36191250-0A918220-EFAA-4B70-AE76-BFD6F5F8ECA7 Q36219817-960F28DB-005A-498F-ACDA-D15E02375865 Q36257543-24BB66C7-5CC3-455C-9F03-D50D31E4CB47 Q36259067-E0F6E4E2-F52B-434E-895B-574BBE71A43A Q36266374-32AABCEA-6BFE-4F7C-8304-FACDC27625AD Q36520046-34D7953D-0CC3-4B58-B411-0BF4011E6D18 Q36903102-71B752F4-EBD6-4CAA-B620-B5E898F44692 Q36942914-2E1B0839-01CD-46CA-9465-285BAF1DF497 Q37029737-1BE350F4-9924-4194-BAF8-1DCD7C49A137 Q37171211-EDCC84F5-A91F-4945-B375-B377812BF8D2 Q37583037-2FEDEF30-C50F-4612-A0F5-617F5ED085B7 Q37689767-54413F42-87CF-4D9D-801F-57EA724FAD29 Q37690941-3F0C6FD1-65A8-4D5C-B72E-331714CCF1A2 Q38024756-C08DF098-A6F0-409D-A8C0-B7274341966C Q38375038-B5B6D7E9-B54C-4937-BA13-5CEE217EDDBD Q38424889-2CE4B3A1-F6F7-4F95-B949-F68A7610AAC3

P2860

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

http://www.wikidata.org/entity/Q35212433

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Receipt of disease-modifying a ...... in Medicare managed care plans

@ast

Receipt of disease-modifying a ...... in Medicare managed care plans

@en

type

label

Receipt of disease-modifying a ...... in Medicare managed care plans

@ast

Receipt of disease-modifying a ...... in Medicare managed care plans

@en

prefLabel

Receipt of disease-modifying a ...... in Medicare managed care plans

@ast

Receipt of disease-modifying a ...... in Medicare managed care plans

@en

P1433

Q35212433-A58B7B5B-71BD-4E5F-A77A-9FE9FE3B5667

P1476

Q35212433-E74E57EE-6788-4729-9A5D-4F063B3882DF

P2093

Q35212433-248E8BA4-A228-4A25-988C-5D3CFDFDC999

Q35212433-263716BF-CEFF-4677-A92B-714E246A216F

Q35212433-5FA2C3FB-7116-47A2-A189-3180D78F1CD3

Q35212433-71D50558-BC12-4756-B18F-E116DECF6ED4

Q35212433-A4F0DB66-E070-40D9-8D35-8E831148019B

Q35212433-B30058CF-3315-4783-ABCC-AF56D8E06911

Q35212433-F0B83C12-497F-4E3C-80C4-4E8AFEDE97EC

P2860

Q35212433-09BD87F3-1620-4C29-861C-91324A1D4293

Q35212433-09FB3ADD-B09A-4240-8E85-2AC75A7B7879

Q35212433-0C224079-B719-47F8-A4B1-11E9761D604D

Q35212433-1F9DC2D1-0B12-4854-8159-A74185054718

Q35212433-20F69DF8-49AF-4F71-A76A-B69D1AB817A2

Q35212433-220B9E05-44F4-4F1C-846C-5243B774E6AC

Q35212433-2211E09B-DEC4-4E17-B488-A5C494FFF75E

Q35212433-3C9C1017-B5E9-4A12-9393-6FCDC959F9B0

Q35212433-45947429-654C-4C16-87E8-AB2B08125390

Q35212433-45B88481-997A-43A2-8085-0807FD9B4BB1

P304

Q35212433-EC1B5471-DD15-4CCA-8573-3DCE5ADE6FCD

P31

Q35212433-1E61D880-6769-455A-8DFE-2E9907E097A5

P356

Q35212433-BCF45112-C30F-4785-912D-9B17BA20D9BC

P407

Q35212433-84075EB4-7699-4ECD-90C9-C40065B60C3C

P433

Q35212433-C05825CB-B218-426B-9B72-BA1DBCB310D8

P478

Q35212433-ED22FBCD-7315-41DE-8B97-59FB50E16FD8

P577

Q35212433-4A77D825-77CB-4F0F-A5C8-FB6E8CB5ADE5

P5875

Q35212433-28A65ADE-66B8-4102-9379-1E9D09F97824

P698

Q35212433-61A9EEE9-5C2F-4447-A933-12A5FFF9D076

P932

Q35212433-CA6BC859-1F65-42E3-BC36-BADB4F1B4ECF

P356

P1433

Journal of the American Medical Association

P1476

Receipt of disease-modifying a ...... in Medicare managed care plans

@en

P2093

Amal N Trivedi

http://www.w3.org/2001/XMLSchema#string

Daniel H Solomon

http://www.w3.org/2001/XMLSchema#string

Edward Yelin

http://www.w3.org/2001/XMLSchema#string

Eliza F Chakravarty

http://www.w3.org/2001/XMLSchema#string

Gabriela Schmajuk

http://www.w3.org/2001/XMLSchema#string

Jinoos Yazdany

http://www.w3.org/2001/XMLSchema#string

Laura Trupin

http://www.w3.org/2001/XMLSchema#string

P2860

Secondary data bases and their use in outcomes research: a review of the area resource file and the Healthcare Cost and Utilization Project.

HCFA's racial and ethnic data: current accuracy and recent improvements.

Addressing racial and ethnic disparities in health care: using federal data to support local programs to eliminate disparities

The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study.

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.

The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus

Regional variations in diagnostic practices

Progress in the treatment of rheumatoid arthritis.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?

P304

480-486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2011.67

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

305

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49802331

http://www.w3.org/2001/XMLSchema#string

P698

21285425

http://www.w3.org/2001/XMLSchema#string

P932

3172813

http://www.w3.org/2001/XMLSchema#string